The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
WSJ Opinion: Potomac Watch
00:00
Navigating the Challenges of Gene Therapy Regulation
This chapter examines the FDA's recent decisions on gene therapy for Duchenne muscular dystrophy, focusing on patient access to new treatments. It also discusses the tension between ensuring safety and fostering innovation, alongside the resignation of a pivotal FDA leader in this context.
Transcript
Play full episode
